Debruyne FM - Search Results

1

4-Year follow-up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer. European Study Group on Neoadjuvant Treatment of Prostate Cancer.

Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR, Witjes WP. Schulman CC, et al. Among authors: debruyne fm. Eur Urol. 2000 Dec;38(6):706-13. doi: 10.1159/000020366. Eur Urol. 2000. PMID: 11111188 Clinical Trial.

2

The value of neoadjuvant therapy in localized prostate cancer.

Witjes WP, Oosterhof GO, Schaafsma HE, Debruyne FM. Witjes WP, et al. Among authors: debruyne fm. Int J Urol. 1995 Mar;2(1):1-5. doi: 10.1111/j.1442-2042.1995.tb00611.x. Int J Urol. 1995. PMID: 7614403 Free article. Review. No abstract available.

3

Risk factors in carcinoma in situ of the urinary bladder. Dutch South East Cooperative Urological Group.

van Gils-Gielen RJ, Witjes WP, Caris CT, Debruyne FM, Witjes JA, Oosterhof GO. van Gils-Gielen RJ, et al. Among authors: debruyne fm. Urology. 1995 Apr;45(4):581-6. doi: 10.1016/s0090-4295(99)80047-8. Urology. 1995. PMID: 7716838 Clinical Trial.

4

A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. The European Study Group on Neoadjuvant Treatment.

Debruyne FM, Witjes WP, Schulman CC, van Cangh PJ, Oosterhof GO. Debruyne FM, et al. Eur Urol. 1994;26 Suppl 1:4. doi: 10.1159/000475423. Eur Urol. 1994. PMID: 7737257 Clinical Trial. No abstract available.

5

Overview of current status of total androgen deprivation in metastasized prostate cancer.

Debruyne FM, Witjes WP. Debruyne FM, et al. Eur Urol. 1993;24 Suppl 2:67-71. Eur Urol. 1993. PMID: 8262129 Review.

6

Neoadjuvant therapy in prostate cancer--is it of any use?

Witjes WP, Horenblas S, Oosterhof GO, Schaafsma HE, Debruyne FM. Witjes WP, et al. Among authors: debruyne fm. Eur Urol. 1993;24(4):433-7. doi: 10.1159/000474346. Eur Urol. 1993. PMID: 8287884 Review.

7

Overview of the current status of total androgen deprivation in metastasized prostate cancer.

Debruyne FM, Witjes WP. Debruyne FM, et al. World J Urol. 1993;11(4):233-6. doi: 10.1007/BF00185076. World J Urol. 1993. PMID: 8312942 Review. No abstract available.

8

The use of 'ultrasensitive' prostate-specific antigen assays in the detection of biochemical recurrence after radical prostatectomy.

van Iersel MP, Thomas CM, Segers MF, Witjes WP, Debruyne FM, Oosterhof GO. van Iersel MP, et al. Among authors: debruyne fm. Br J Urol. 1996 Mar;77(3):418-22. doi: 10.1046/j.1464-410x.1996.91017.x. Br J Urol. 1996. PMID: 8814849 Free article.

9

Clinical implications of the rise and fall of prostate specific antigen after laser prostatectomy.

van Iersel MP, Thomas CM, Witjes WP, de Graaf R, de la Rosette JJ, Debruyne FM. van Iersel MP, et al. Among authors: debruyne fm. Br J Urol. 1996 Nov;78(5):742-6. doi: 10.1046/j.1464-410x.1996.21914.x. Br J Urol. 1996. PMID: 8976771

10

Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostatic carcinoma. The European Study Group on Neoadjuvant Treatment of Prostate Cancer.

Witjes WP, Schulman CC, Debruyne FM. Witjes WP, et al. Among authors: debruyne fm. Urology. 1997 Mar;49(3A Suppl):65-9. doi: 10.1016/s0090-4295(97)00171-4. Urology. 1997. PMID: 9123739 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

670 results

Search Page

Filters